NEW YORK, Dec. 9, 2023 /PRNewswire/ — The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows. The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight infections by making proteins that remove germs. The cancerous cells build… Continue reading New Hybrid Treatment Forces Cancer Cells to Starve
Category: Newswire
AV-Comparatives veröffentlicht die Ergebnisse der 2023 Advanced Threat Protection-Tests für marktführende Cybersecurity-Produkte für Unternehmen und Verbraucher
AV-Comparatives hat die Ergebnisse des 2023 Advanced Threat Protection Tests für 15 Sicherheitsprodukte für Verbraucher und Unternehmen veröffentlicht „Die Tests zeigen, dass führende Sicherheitssoftware bei der Abwehr von gezielten Bedrohungen hervorragend abschneidet, wobei die Anbieter ihre Schutzmaßnahmen kontinuierlich verbessern.” – Andreas Clementi, Gründer und CEO, AV-Comparatives INNSBRUCK, Österreich, 27. November 2023 /PRNewswire/ — Der von… Continue reading AV-Comparatives veröffentlicht die Ergebnisse der 2023 Advanced Threat Protection-Tests für marktführende Cybersecurity-Produkte für Unternehmen und Verbraucher
VyOS Networks traz o VyOS Universal Router para a Equinix Network Edge e a Equinix Metal
POWAY, Califórnia, 9 de dezembro de 2023 /PRNewswire/ — A VyOS Networks anunciou que está trazendo o VyOS Universal Router para a Plataforma Equinix. Essa disponibilidade expandida visa dar suporte ao cenário de infraestrutura de rede, integrando as soluções de rede flexíveis e robustas da VyOS com o ecossistema de interconexão global da Equinix. O VyOS Universal… Continue reading VyOS Networks traz o VyOS Universal Router para a Equinix Network Edge e a Equinix Metal
Il Gruppo Menarini presenta a SABCS 2023 nuovi dati dallo studio clinico EMERALD su ORSERDU® (elacestrant) sulla sopravvivenza libera da progressione in sottogruppi clinicamente rilevanti di pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- con mutazioni di ESR1
Questa nuova analisi post-hoc dello studio di fase 3 EMERALD ha valutato elacestrant nella popolazione endocrino-sensibile (durata dell’inibitore delle CDK4/6 di almeno 12 mesi) affetta da carcinomi con mutazioni di ESR1. Questa analisi mostra un miglioramento clinicamente significativo nella sopravvivenza libera da progressione nei sottogruppi studiati, tra cui i pazienti con metastasi ossee, epatiche e/o polmonari, quelli con… Continue reading Il Gruppo Menarini presenta a SABCS 2023 nuovi dati dallo studio clinico EMERALD su ORSERDU® (elacestrant) sulla sopravvivenza libera da progressione in sottogruppi clinicamente rilevanti di pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- con mutazioni di ESR1
Last Legend Off the Line: 2023 Chrysler 300C Ends Production
AUBURN HILLS, Mich., Dec. 9, 2023 /PRNewswire/ — Continue Reading The last of a legend, the Chrysler 300C, rolled off the line at the Brampton (Ontario) Assembly Plant, with Brampton team members gathered to commemorate final production of the HEMI®-powered vehicle — a Velvet Red 2023 Chrysler 300C. Final 2023 Chrysler 300C model rolls off… Continue reading Last Legend Off the Line: 2023 Chrysler 300C Ends Production
The NDC Partnership Joins the COP28 and CBD COP15 Presidencies and Nearly 30 Countries and Coalitions Advancing Integrated Action for Climate and Nature
DUBAI, UAE, Dec. 9, 2023 /PRNewswire/ — The NDC Partnership, the United Arab Emirates as the United Nations Framework Convention on Climate Change (UNFCCC) COP28 Presidency, the People’s Republic of China as the United Nations Convention on Biological Diversity (CBD) COP15 Presidency, and nearly 30 countries and coalitions endorsed the COP28 Joint Statement on Climate,… Continue reading The NDC Partnership Joins the COP28 and CBD COP15 Presidencies and Nearly 30 Countries and Coalitions Advancing Integrated Action for Climate and Nature
The NDC Partnership Joins the COP28 and CBD COP15 Presidencies and Nearly 30 Countries and Coalitions Advancing Integrated Action for Climate and Nature
DUBAI, UAE, Dec. 9, 2023 /PRNewswire/ — The NDC Partnership, the United Arab Emirates as the United Nations Framework Convention on Climate Change (UNFCCC) COP28 Presidency, the People’s Republic of China as the United Nations Convention on Biological Diversity (CBD) COP15 Presidency, and nearly 30 countries and coalitions endorsed the COP28 Joint Statement on Climate,… Continue reading The NDC Partnership Joins the COP28 and CBD COP15 Presidencies and Nearly 30 Countries and Coalitions Advancing Integrated Action for Climate and Nature
World Automotive Chip Innovation Conference 2023 in Binhu, Wuxi
WUXI, China, 9. Dezember 2023 /PRNewswire/ — Vom 5. bis 6. Dezember wurden die World Automotive Chip Innovation Conference 2023 und der China Automotive Chip Summit 2023 in Binhu, einem Stadtbezirk von Wuxi, China, ausgerichtet. Im Mittelpunkt der Konferenz standen Spitzentechnologien und die Herausforderungen im Bereich der Halbleiterkomponenten für die Automobilbranche. In Diskussionsrunden kamen neue Ansätze bei der… Continue reading World Automotive Chip Innovation Conference 2023 in Binhu, Wuxi
InnVernia recebe prêmio nacional pelo vinho Chardonnay Premium
Primeiro Chardonnay produzido pela marca foi classificado pela Confederação da Agricultura e Pecuária do Brasil em segundo lugar na categoria SÂO PAULO, 9 de dezembro de 2023 /PRNewswire/ — A vinícola InnVernia foi premiada pela Confederação da Agricultura e Pecuária do Brasil (CNA) na última quinta-feira (07), pela produção do seu vinho Chardonnay Premium. Esse… Continue reading InnVernia recebe prêmio nacional pelo vinho Chardonnay Premium
Blueprint Medicines’ Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
— HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company’s SM franchise leadership — CAMBRIDGE, Mass., Dec. 9, 2023 /PRNewswire/ — Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and treatment… Continue reading Blueprint Medicines’ Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting